Prophylactic effects of chitin microparticles on highly pathogenic H5N1 influenza virus.
Identifieur interne : 001B45 ( PubMed/Curation ); précédent : 001B44; suivant : 001B46Prophylactic effects of chitin microparticles on highly pathogenic H5N1 influenza virus.
Auteurs : Takeshi Ichinohe [Japon] ; Noriyo Nagata ; Peter Strong ; Shin-Ichi Tamura ; Hidehiro Takahashi ; Ai Ninomiya ; Masaki Imai ; Takato Odagiri ; Masato Tashiro ; Hirofumi Sawa ; Joe Chiba ; Takeshi Kurata ; Tetsutaro Sata ; Hideki HasegawaSource :
- Journal of medical virology [ 0146-6615 ] ; 2007.
Descripteurs français
- KwdFr :
- Administration par voie nasale, Analyse de survie, Animaux, Antiviraux (), Antiviraux (administration et posologie), Antiviraux (immunologie), Cellules tueuses naturelles (immunologie), Chimiokine CXCL10, Chimiokines CXC (analyse), Chimiokines CXC (immunologie), Chitine (), Chitine (administration et posologie), Chitine (immunologie), Femelle, Immunité innée, Immunité muqueuse, Infections à Orthomyxoviridae (), Infections à Orthomyxoviridae (immunologie), Interleukine-6 (analyse), Interleukine-6 (immunologie), Ligand TRAIL (biosynthèse), Modèles animaux de maladie humaine, Muqueuse nasale (), Muqueuse nasale (immunologie), Noeuds lymphatiques (immunologie), Organismes exempts d'organismes pathogènes spécifiques, Souris, Souris de lignée BALB C, Sous-type H1N1 du virus de la grippe A (immunologie), Sous-type H5N1 du virus de la grippe A (immunologie).
- MESH :
- administration et posologie : Antiviraux, Chitine.
- analyse : Chimiokines CXC, Interleukine-6.
- biosynthèse : Ligand TRAIL.
- immunologie : Antiviraux, Cellules tueuses naturelles, Chimiokines CXC, Chitine, Infections à Orthomyxoviridae, Interleukine-6, Muqueuse nasale, Noeuds lymphatiques, Sous-type H1N1 du virus de la grippe A, Sous-type H5N1 du virus de la grippe A.
- Administration par voie nasale, Analyse de survie, Animaux, Antiviraux, Chimiokine CXCL10, Chitine, Femelle, Immunité innée, Immunité muqueuse, Infections à Orthomyxoviridae, Modèles animaux de maladie humaine, Muqueuse nasale, Organismes exempts d'organismes pathogènes spécifiques, Souris, Souris de lignée BALB C.
English descriptors
- KwdEn :
- Administration, Intranasal, Animals, Antiviral Agents (administration & dosage), Antiviral Agents (chemistry), Antiviral Agents (immunology), Chemokine CXCL10, Chemokines, CXC (analysis), Chemokines, CXC (immunology), Chitin (administration & dosage), Chitin (chemistry), Chitin (immunology), Disease Models, Animal, Female, Immunity, Innate, Immunity, Mucosal, Influenza A Virus, H1N1 Subtype (immunology), Influenza A Virus, H5N1 Subtype (immunology), Interleukin-6 (analysis), Interleukin-6 (immunology), Killer Cells, Natural (immunology), Lymph Nodes (immunology), Mice, Mice, Inbred BALB C, Nasal Mucosa (chemistry), Nasal Mucosa (immunology), Orthomyxoviridae Infections (immunology), Orthomyxoviridae Infections (prevention & control), Specific Pathogen-Free Organisms, Survival Analysis, TNF-Related Apoptosis-Inducing Ligand (biosynthesis).
- MESH :
- chemical , administration & dosage : Antiviral Agents, Chitin.
- chemical , analysis : Chemokines, CXC, Interleukin-6.
- chemical , biosynthesis : TNF-Related Apoptosis-Inducing Ligand.
- chemical , chemistry : Antiviral Agents, Chitin.
- chemical , immunology : Antiviral Agents, Chemokines, CXC, Chitin, Interleukin-6.
- chemistry : Nasal Mucosa.
- immunology : Influenza A Virus, H1N1 Subtype, Influenza A Virus, H5N1 Subtype, Killer Cells, Natural, Lymph Nodes, Nasal Mucosa, Orthomyxoviridae Infections.
- prevention & control : Orthomyxoviridae Infections.
- Administration, Intranasal, Animals, Chemokine CXCL10, Disease Models, Animal, Female, Immunity, Innate, Immunity, Mucosal, Mice, Mice, Inbred BALB C, Specific Pathogen-Free Organisms, Survival Analysis.
Abstract
Highly pathogenic avian influenza virus (H5N1) is an emerging pathogen with the potential to cause great harm to humans, and there is concern about the potential for a new influenza pandemic. This virus is resistant to the antiviral effects of interferons and tumor necrosis factor-alpha. However, the mechanism of interferon-independent protective innate immunity is not well understood. The prophylactic effects of chitin microparticles as a stimulator of innate mucosal immunity against a recently obtained strain of H5N1 influenza virus infection were examined in mice. Clinical parameters and the survival rate of mice treated by intranasal application of chitin microparticles were significantly improved compared to non-treated mice after a lethal influenza virus challenge. Flow cytometric analysis revealed that the number of natural killer cells that expressed tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and that had migrated into the cervical lymph node was markedly increased (26-fold) after intranasal treatment with chitin microparticles. In addition, the level of IL-6 and interferon-gamma-inducible protein-10 (IP-10) in the nasal mucosa after H5N1 influenza virus challenge was decreased by prophylactic treatment with chitin microparticles. These results suggest that prophylactic intranasal administration of chitin microparticles enhanced the local accumulation of natural killer cells and suppressed hyper-induction of cytokines, resulting in an innate immune response to prevent pathogenesis of H5N1 influenza virus.
DOI: 10.1002/jmv.20837
PubMed: 17457919
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001B45
Links to Exploration step
pubmed:17457919Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Prophylactic effects of chitin microparticles on highly pathogenic H5N1 influenza virus.</title>
<author><name sortKey="Ichinohe, Takeshi" sort="Ichinohe, Takeshi" uniqKey="Ichinohe T" first="Takeshi" last="Ichinohe">Takeshi Ichinohe</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pathology, National Institute of Infectious Diseases, Gakuen, Musashimurayama-shi, Tokyo, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Pathology, National Institute of Infectious Diseases, Gakuen, Musashimurayama-shi, Tokyo</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Nagata, Noriyo" sort="Nagata, Noriyo" uniqKey="Nagata N" first="Noriyo" last="Nagata">Noriyo Nagata</name>
</author>
<author><name sortKey="Strong, Peter" sort="Strong, Peter" uniqKey="Strong P" first="Peter" last="Strong">Peter Strong</name>
</author>
<author><name sortKey="Tamura, Shin Ichi" sort="Tamura, Shin Ichi" uniqKey="Tamura S" first="Shin-Ichi" last="Tamura">Shin-Ichi Tamura</name>
</author>
<author><name sortKey="Takahashi, Hidehiro" sort="Takahashi, Hidehiro" uniqKey="Takahashi H" first="Hidehiro" last="Takahashi">Hidehiro Takahashi</name>
</author>
<author><name sortKey="Ninomiya, Ai" sort="Ninomiya, Ai" uniqKey="Ninomiya A" first="Ai" last="Ninomiya">Ai Ninomiya</name>
</author>
<author><name sortKey="Imai, Masaki" sort="Imai, Masaki" uniqKey="Imai M" first="Masaki" last="Imai">Masaki Imai</name>
</author>
<author><name sortKey="Odagiri, Takato" sort="Odagiri, Takato" uniqKey="Odagiri T" first="Takato" last="Odagiri">Takato Odagiri</name>
</author>
<author><name sortKey="Tashiro, Masato" sort="Tashiro, Masato" uniqKey="Tashiro M" first="Masato" last="Tashiro">Masato Tashiro</name>
</author>
<author><name sortKey="Sawa, Hirofumi" sort="Sawa, Hirofumi" uniqKey="Sawa H" first="Hirofumi" last="Sawa">Hirofumi Sawa</name>
</author>
<author><name sortKey="Chiba, Joe" sort="Chiba, Joe" uniqKey="Chiba J" first="Joe" last="Chiba">Joe Chiba</name>
</author>
<author><name sortKey="Kurata, Takeshi" sort="Kurata, Takeshi" uniqKey="Kurata T" first="Takeshi" last="Kurata">Takeshi Kurata</name>
</author>
<author><name sortKey="Sata, Tetsutaro" sort="Sata, Tetsutaro" uniqKey="Sata T" first="Tetsutaro" last="Sata">Tetsutaro Sata</name>
</author>
<author><name sortKey="Hasegawa, Hideki" sort="Hasegawa, Hideki" uniqKey="Hasegawa H" first="Hideki" last="Hasegawa">Hideki Hasegawa</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2007">2007</date>
<idno type="RBID">pubmed:17457919</idno>
<idno type="pmid">17457919</idno>
<idno type="doi">10.1002/jmv.20837</idno>
<idno type="wicri:Area/PubMed/Corpus">001B45</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001B45</idno>
<idno type="wicri:Area/PubMed/Curation">001B45</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001B45</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Prophylactic effects of chitin microparticles on highly pathogenic H5N1 influenza virus.</title>
<author><name sortKey="Ichinohe, Takeshi" sort="Ichinohe, Takeshi" uniqKey="Ichinohe T" first="Takeshi" last="Ichinohe">Takeshi Ichinohe</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pathology, National Institute of Infectious Diseases, Gakuen, Musashimurayama-shi, Tokyo, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Pathology, National Institute of Infectious Diseases, Gakuen, Musashimurayama-shi, Tokyo</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Nagata, Noriyo" sort="Nagata, Noriyo" uniqKey="Nagata N" first="Noriyo" last="Nagata">Noriyo Nagata</name>
</author>
<author><name sortKey="Strong, Peter" sort="Strong, Peter" uniqKey="Strong P" first="Peter" last="Strong">Peter Strong</name>
</author>
<author><name sortKey="Tamura, Shin Ichi" sort="Tamura, Shin Ichi" uniqKey="Tamura S" first="Shin-Ichi" last="Tamura">Shin-Ichi Tamura</name>
</author>
<author><name sortKey="Takahashi, Hidehiro" sort="Takahashi, Hidehiro" uniqKey="Takahashi H" first="Hidehiro" last="Takahashi">Hidehiro Takahashi</name>
</author>
<author><name sortKey="Ninomiya, Ai" sort="Ninomiya, Ai" uniqKey="Ninomiya A" first="Ai" last="Ninomiya">Ai Ninomiya</name>
</author>
<author><name sortKey="Imai, Masaki" sort="Imai, Masaki" uniqKey="Imai M" first="Masaki" last="Imai">Masaki Imai</name>
</author>
<author><name sortKey="Odagiri, Takato" sort="Odagiri, Takato" uniqKey="Odagiri T" first="Takato" last="Odagiri">Takato Odagiri</name>
</author>
<author><name sortKey="Tashiro, Masato" sort="Tashiro, Masato" uniqKey="Tashiro M" first="Masato" last="Tashiro">Masato Tashiro</name>
</author>
<author><name sortKey="Sawa, Hirofumi" sort="Sawa, Hirofumi" uniqKey="Sawa H" first="Hirofumi" last="Sawa">Hirofumi Sawa</name>
</author>
<author><name sortKey="Chiba, Joe" sort="Chiba, Joe" uniqKey="Chiba J" first="Joe" last="Chiba">Joe Chiba</name>
</author>
<author><name sortKey="Kurata, Takeshi" sort="Kurata, Takeshi" uniqKey="Kurata T" first="Takeshi" last="Kurata">Takeshi Kurata</name>
</author>
<author><name sortKey="Sata, Tetsutaro" sort="Sata, Tetsutaro" uniqKey="Sata T" first="Tetsutaro" last="Sata">Tetsutaro Sata</name>
</author>
<author><name sortKey="Hasegawa, Hideki" sort="Hasegawa, Hideki" uniqKey="Hasegawa H" first="Hideki" last="Hasegawa">Hideki Hasegawa</name>
</author>
</analytic>
<series><title level="j">Journal of medical virology</title>
<idno type="ISSN">0146-6615</idno>
<imprint><date when="2007" type="published">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Intranasal</term>
<term>Animals</term>
<term>Antiviral Agents (administration & dosage)</term>
<term>Antiviral Agents (chemistry)</term>
<term>Antiviral Agents (immunology)</term>
<term>Chemokine CXCL10</term>
<term>Chemokines, CXC (analysis)</term>
<term>Chemokines, CXC (immunology)</term>
<term>Chitin (administration & dosage)</term>
<term>Chitin (chemistry)</term>
<term>Chitin (immunology)</term>
<term>Disease Models, Animal</term>
<term>Female</term>
<term>Immunity, Innate</term>
<term>Immunity, Mucosal</term>
<term>Influenza A Virus, H1N1 Subtype (immunology)</term>
<term>Influenza A Virus, H5N1 Subtype (immunology)</term>
<term>Interleukin-6 (analysis)</term>
<term>Interleukin-6 (immunology)</term>
<term>Killer Cells, Natural (immunology)</term>
<term>Lymph Nodes (immunology)</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Nasal Mucosa (chemistry)</term>
<term>Nasal Mucosa (immunology)</term>
<term>Orthomyxoviridae Infections (immunology)</term>
<term>Orthomyxoviridae Infections (prevention & control)</term>
<term>Specific Pathogen-Free Organisms</term>
<term>Survival Analysis</term>
<term>TNF-Related Apoptosis-Inducing Ligand (biosynthesis)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Administration par voie nasale</term>
<term>Analyse de survie</term>
<term>Animaux</term>
<term>Antiviraux ()</term>
<term>Antiviraux (administration et posologie)</term>
<term>Antiviraux (immunologie)</term>
<term>Cellules tueuses naturelles (immunologie)</term>
<term>Chimiokine CXCL10</term>
<term>Chimiokines CXC (analyse)</term>
<term>Chimiokines CXC (immunologie)</term>
<term>Chitine ()</term>
<term>Chitine (administration et posologie)</term>
<term>Chitine (immunologie)</term>
<term>Femelle</term>
<term>Immunité innée</term>
<term>Immunité muqueuse</term>
<term>Infections à Orthomyxoviridae ()</term>
<term>Infections à Orthomyxoviridae (immunologie)</term>
<term>Interleukine-6 (analyse)</term>
<term>Interleukine-6 (immunologie)</term>
<term>Ligand TRAIL (biosynthèse)</term>
<term>Modèles animaux de maladie humaine</term>
<term>Muqueuse nasale ()</term>
<term>Muqueuse nasale (immunologie)</term>
<term>Noeuds lymphatiques (immunologie)</term>
<term>Organismes exempts d'organismes pathogènes spécifiques</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
<term>Sous-type H1N1 du virus de la grippe A (immunologie)</term>
<term>Sous-type H5N1 du virus de la grippe A (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiviral Agents</term>
<term>Chitin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Chemokines, CXC</term>
<term>Interleukin-6</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en"><term>TNF-Related Apoptosis-Inducing Ligand</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Antiviral Agents</term>
<term>Chitin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antiviral Agents</term>
<term>Chemokines, CXC</term>
<term>Chitin</term>
<term>Interleukin-6</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antiviraux</term>
<term>Chitine</term>
</keywords>
<keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Chimiokines CXC</term>
<term>Interleukine-6</term>
</keywords>
<keywords scheme="MESH" qualifier="biosynthèse" xml:lang="fr"><term>Ligand TRAIL</term>
</keywords>
<keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>Nasal Mucosa</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Antiviraux</term>
<term>Cellules tueuses naturelles</term>
<term>Chimiokines CXC</term>
<term>Chitine</term>
<term>Infections à Orthomyxoviridae</term>
<term>Interleukine-6</term>
<term>Muqueuse nasale</term>
<term>Noeuds lymphatiques</term>
<term>Sous-type H1N1 du virus de la grippe A</term>
<term>Sous-type H5N1 du virus de la grippe A</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term>
<term>Influenza A Virus, H5N1 Subtype</term>
<term>Killer Cells, Natural</term>
<term>Lymph Nodes</term>
<term>Nasal Mucosa</term>
<term>Orthomyxoviridae Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Orthomyxoviridae Infections</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Administration, Intranasal</term>
<term>Animals</term>
<term>Chemokine CXCL10</term>
<term>Disease Models, Animal</term>
<term>Female</term>
<term>Immunity, Innate</term>
<term>Immunity, Mucosal</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Specific Pathogen-Free Organisms</term>
<term>Survival Analysis</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Administration par voie nasale</term>
<term>Analyse de survie</term>
<term>Animaux</term>
<term>Antiviraux</term>
<term>Chimiokine CXCL10</term>
<term>Chitine</term>
<term>Femelle</term>
<term>Immunité innée</term>
<term>Immunité muqueuse</term>
<term>Infections à Orthomyxoviridae</term>
<term>Modèles animaux de maladie humaine</term>
<term>Muqueuse nasale</term>
<term>Organismes exempts d'organismes pathogènes spécifiques</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Highly pathogenic avian influenza virus (H5N1) is an emerging pathogen with the potential to cause great harm to humans, and there is concern about the potential for a new influenza pandemic. This virus is resistant to the antiviral effects of interferons and tumor necrosis factor-alpha. However, the mechanism of interferon-independent protective innate immunity is not well understood. The prophylactic effects of chitin microparticles as a stimulator of innate mucosal immunity against a recently obtained strain of H5N1 influenza virus infection were examined in mice. Clinical parameters and the survival rate of mice treated by intranasal application of chitin microparticles were significantly improved compared to non-treated mice after a lethal influenza virus challenge. Flow cytometric analysis revealed that the number of natural killer cells that expressed tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and that had migrated into the cervical lymph node was markedly increased (26-fold) after intranasal treatment with chitin microparticles. In addition, the level of IL-6 and interferon-gamma-inducible protein-10 (IP-10) in the nasal mucosa after H5N1 influenza virus challenge was decreased by prophylactic treatment with chitin microparticles. These results suggest that prophylactic intranasal administration of chitin microparticles enhanced the local accumulation of natural killer cells and suppressed hyper-induction of cytokines, resulting in an innate immune response to prevent pathogenesis of H5N1 influenza virus.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17457919</PMID>
<DateCompleted><Year>2007</Year>
<Month>07</Month>
<Day>30</Day>
</DateCompleted>
<DateRevised><Year>2008</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0146-6615</ISSN>
<JournalIssue CitedMedium="Print"><Volume>79</Volume>
<Issue>6</Issue>
<PubDate><Year>2007</Year>
<Month>Jun</Month>
</PubDate>
</JournalIssue>
<Title>Journal of medical virology</Title>
<ISOAbbreviation>J. Med. Virol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Prophylactic effects of chitin microparticles on highly pathogenic H5N1 influenza virus.</ArticleTitle>
<Pagination><MedlinePgn>811-9</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Highly pathogenic avian influenza virus (H5N1) is an emerging pathogen with the potential to cause great harm to humans, and there is concern about the potential for a new influenza pandemic. This virus is resistant to the antiviral effects of interferons and tumor necrosis factor-alpha. However, the mechanism of interferon-independent protective innate immunity is not well understood. The prophylactic effects of chitin microparticles as a stimulator of innate mucosal immunity against a recently obtained strain of H5N1 influenza virus infection were examined in mice. Clinical parameters and the survival rate of mice treated by intranasal application of chitin microparticles were significantly improved compared to non-treated mice after a lethal influenza virus challenge. Flow cytometric analysis revealed that the number of natural killer cells that expressed tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and that had migrated into the cervical lymph node was markedly increased (26-fold) after intranasal treatment with chitin microparticles. In addition, the level of IL-6 and interferon-gamma-inducible protein-10 (IP-10) in the nasal mucosa after H5N1 influenza virus challenge was decreased by prophylactic treatment with chitin microparticles. These results suggest that prophylactic intranasal administration of chitin microparticles enhanced the local accumulation of natural killer cells and suppressed hyper-induction of cytokines, resulting in an innate immune response to prevent pathogenesis of H5N1 influenza virus.</AbstractText>
<CopyrightInformation>(c) 2007 Wiley-Liss, Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ichinohe</LastName>
<ForeName>Takeshi</ForeName>
<Initials>T</Initials>
<AffiliationInfo><Affiliation>Department of Pathology, National Institute of Infectious Diseases, Gakuen, Musashimurayama-shi, Tokyo, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Nagata</LastName>
<ForeName>Noriyo</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y"><LastName>Strong</LastName>
<ForeName>Peter</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y"><LastName>Tamura</LastName>
<ForeName>Shin-ichi</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y"><LastName>Takahashi</LastName>
<ForeName>Hidehiro</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y"><LastName>Ninomiya</LastName>
<ForeName>Ai</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y"><LastName>Imai</LastName>
<ForeName>Masaki</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Odagiri</LastName>
<ForeName>Takato</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y"><LastName>Tashiro</LastName>
<ForeName>Masato</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Sawa</LastName>
<ForeName>Hirofumi</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y"><LastName>Chiba</LastName>
<ForeName>Joe</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y"><LastName>Kurata</LastName>
<ForeName>Takeshi</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y"><LastName>Sata</LastName>
<ForeName>Tetsutaro</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y"><LastName>Hasegawa</LastName>
<ForeName>Hideki</ForeName>
<Initials>H</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>J Med Virol</MedlineTA>
<NlmUniqueID>7705876</NlmUniqueID>
<ISSNLinking>0146-6615</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D054357">Chemokine CXCL10</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019743">Chemokines, CXC</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053221">TNF-Related Apoptosis-Inducing Ligand</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C505654">Tnfsf10 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>1398-61-4</RegistryNumber>
<NameOfSubstance UI="D002686">Chitin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000281" MajorTopicYN="N">Administration, Intranasal</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D054357" MajorTopicYN="N">Chemokine CXCL10</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019743" MajorTopicYN="N">Chemokines, CXC</DescriptorName>
<QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002686" MajorTopicYN="N">Chitin</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018928" MajorTopicYN="N">Immunity, Mucosal</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053124" MajorTopicYN="N">Influenza A Virus, H5N1 Subtype</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
<QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007694" MajorTopicYN="N">Killer Cells, Natural</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008198" MajorTopicYN="N">Lymph Nodes</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009297" MajorTopicYN="N">Nasal Mucosa</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009976" MajorTopicYN="N">Orthomyxoviridae Infections</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013047" MajorTopicYN="N">Specific Pathogen-Free Organisms</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053221" MajorTopicYN="N">TNF-Related Apoptosis-Inducing Ligand</DescriptorName>
<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year>
<Month>4</Month>
<Day>26</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2007</Year>
<Month>7</Month>
<Day>31</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2007</Year>
<Month>4</Month>
<Day>26</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">17457919</ArticleId>
<ArticleId IdType="doi">10.1002/jmv.20837</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B45 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001B45 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= PandemieGrippaleV1 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:17457919 |texte= Prophylactic effects of chitin microparticles on highly pathogenic H5N1 influenza virus. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:17457919" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a PandemieGrippaleV1
![]() | This area was generated with Dilib version V0.6.34. | ![]() |